Role of AKT signaling in DNA repair and clinical response to cancer therapy

Neuro-Oncology

Volumn 16, Issue 10, 2014, Pages 1313-1323

  Liu, Qun ^a   Turner, Kristen M ^a,b,c   Yung, W K Alfred ^b   Chen, Kexin ^a   Zhang, Wei ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

Cancer; DNA damage; DNA repair: AKT; Treatment resistance

Indexed keywords

PROTEIN KINASE B;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL NUCLEUS; DNA ADDUCT; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; GENOTOXICITY; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; DNA DAMAGE; DRUG RESISTANCE; GENETICS; MOUSE; NEOPLASMS;

ANIMALS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84925256439     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou058     Document Type: Article

References (100)

1. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A. 1977;74(7):3065-3067.
2. Ruan G-X, Kazlauskas A. Focus on molecules: Akt (PKB). Exp Eye Res. 2011;93(5):570-571.
3. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009;8(16):2502-2508.
4. Sale EM, Sale GJ. Protein kinase B: signalling roles and therapeutic targeting. Cell Mol Life Sci. 2008;65(1):113-127.
5. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515-1527.
6. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
8. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098-1101.
9. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000;97(7):3207-3212.
10. Leslie NR, Batty IH, Maccario H, et al. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene. 2008;27(41):5464-5476.
11. Ruvolo PP, Qui YH, Coombes KR, et al. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011;25(11):1711-1717.
12. Brognard J, Sierecki E, Gao T, et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25(6):917-931.
13. Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 2013;32(5):253-265.
14. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
15. Bellacosa A, Kumar CC, Di Cristofano A, et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29-86.
16. Hafsi S, Pezzino FM, Candido S, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 2012;40(3):639-644.
17. Tanaka S, Louis DN, Curry WT, et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2012;10(1):14-26.
18. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987;84(14):5034-5037.
19. Pedrero J M G, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005;114(2):242-248.
20. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64(19):7002-7010.
21. Brugge J, Hung M-C, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007;12(2):104-107.
22. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-7464.
23. Sami A, Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumor Biol. 2013;34(4):1991-2002.
24. Burris HA. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013;71(4):829-842.
25. Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72-76.
26. Takeuchi S, Wang W, Li Q, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181(3):1034-1043.
27. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13(17):5150-5155.
28. Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br Jf Cancer. 2012;106(8):1367-1373.
29. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A. 2009;106(46):19503-19508.
30. Cavazzoni A, Bonelli MA, Fumarola C, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012;323(1):77-87.
31. Broxterman HJ, Gotink KJ, Verheul H M W. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009;12(4-5):114-126.
32. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73-99.
33. Hirose Y, Katayama M, Mirzoeva OK, et al. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 2005;65(11):4861-4869.
34. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
35. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38 (MAPK) phosphorylation of the EGF receptor. Oncogene. 2006;25(56):7381-7390.
36. Mabuchi S, Ohmichi M, Kimura A, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277(36):33490-33500.
37. Taylor JR, Lehmann BD, Chappell WH, et al. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget. 2011;2(8):610-626.
38. Ng S S W, Tsao MS, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000;60(19):5451-5455.
39. Tomioka A, Tanaka M, De Velasco MA, et al. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther. 2008;7(7):1864-1870.
40. Li H-F, Kim J-S, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 2009;4:43.
41. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19(2):238-245.
42. Zhang D, Wang H-B, Brinkman KL, et al. Strategies for targeting the DNA damage response for cancer therapeutics. Chin J Cancer. 2012;31(8):359-363.
43. Xu N, Lao Y, Zhang Y, et al. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012;2012:951724.
44. Bozulic L, Surucu B, Hynx D, et al. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008;30(2):203-213.
45. Surucu B, Bozulic L, Hynx D, et al. In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem. 2008;283(44):30025-30033.
46. Park J, Feng J, Li Y, et al. DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. J Biol Chem. 2009;284(10):6169-6174.
47. Viniegra JG, Martínez N, Modirassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005;280(6):4029-4036.
48. Fraser M, Harding SM, Zhao H, et al. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle. 2011;10(13):2218-2232.
49. Toulany M, Schickfluss T-A, Fattah KR, et al. Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation. Radiother Oncol. 2011;101(1):140-146.
50. Golding SE, Morgan RN, Adams BR, et al. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther. 2009;8(8):730-738.
51. Caporali S, Levati L, Starace G, et al. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol. 2008;74(1):173-183.
52. Sousa FG, Matuo R, Soares DG, et al. PARPs and the DNA damage response. Carcinogenesis. 2012;33(8):1433-1440.
53. Ethier C, Tardif M, Arul L, et al. PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent. PloS One. 2012;7(10):e47978.
54. Virág L. Poly (ADP-ribosyl) ation in asthma and other lung diseases. Pharmacol Res. 2005;52(1):83-92.
55. Chae H-D, Broxmeyer HE. SIRT1 deficiency downregulates PTEN/JNK/FOXO1 pathway to block reactive oxygen species-induced apoptosis in mouse embryonic stem cells. Stem Cells Dev. 2011;20(7):1277-1285.
56. Sundaresan NR, Pillai VB, Wolfgeher D, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011;4(182):ra46.
57. Wang S, Wang H, Davis BC, et al. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun. 2011;412(2):379-384.
58. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97(7):3028-3033.
59. Saji M, Vasko V, Kada F, et al. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun. 2005;332(1):167-173.
60. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A. 2008;105(22):7785-7790.
61. Kikani CK, Dong LQ, Liu F. 'New'-clear functions of PDK1: beyond a master kinase in the cytosol? J Cell Biochem. 2005;96(6):1157-1162.
62. Liu J, Stevens PD, Gao T. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem. 2011;286(8):6510-6520.
63. Stronach EA, Chen M, Maginn EN, et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011;13(11):1069-1080.
64. Trotman LC, Alimonti A, Scaglioni PP, et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006;441(7092):523-527.
65. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24(23):3799-3808.
66. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12(2):104-120.
67. Kaina B, Christmann M, Naumann S, et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6(8):1079-1099.
68. Stojic L, Cejka P, Jiricny J. High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle. 2005;4(3):473-477.
69. Jia J, Zhang Y, Cai J, et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25(6):1498-1504.
70. Jamieson ER, Lippard SJ. Structure, recognition, and processing of Cisplatin-DNA Adducts. Chem Rev. 1999;99(9):2467-2498.
71. Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, et al. cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res. 1987;47(11):3000-3004.
72. Roos WP, Kaina B. DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332(2):237-248.
73. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.
74. Huang W-C, Chen C-C. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 2005;25(15):6592-6602.
75. Wang QE, Han C, Zhao R, et al. p38 MAPK- and Akt-mediated p300 phosphorylation regulates its degradation to facilitate nucleotide excision repair. Nucleic Acids Res. 2013;41(3):1722-1733.
76. Ming M, Shea CR, Guo X, et al. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proc Natl Acad Sci U S A. 2010;107(52):22623-22628.
77. Nouspikel T. DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66(6):994-1009.
78. Cleaver JE, Thompson LH, Richardson AS, et al. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat. 1999;14(1):9-22.
79. Budden T, Bowden N. The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis. Int JMol Sci. 2013;14(1):1132-1151.
80. Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci. 2011;36(3):133-140.
81. Shen C, Oswald D, Phelps D, et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks. Cancer Res. 2013;73(11):3393-3401.
82. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A. 2003;100(9):5057-5062.
83. Cadet J, Delatour T, Douki T, et al. Hydroxyl radicals and DNA base damage. Mutat Res. 1999;424(1-2):9-21.
84. Weterings E, Chen DJ. DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys? J Cell Biol. 2007;179(2):183-186.
85. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181-211.
86. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77(1):229-257.
87. Neal JA, Meek K. Choosing the right path: does DNA-PK help make the decision? Mutat Res. 2011;711(1-2):73-86.
88. Chapman JR, Taylor M R G, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497-510.
89. Lavin MF, Kozlov S. DNA damage-induced signalling in ataxiatelangiectasia and related syndromes. Radiother Oncol. 2007;83(3):231-237.
90. Toulany M, Lee K-J, Fattah KR, et al. Akt promotes postirradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res. 2012;10(7):945-957.
91. Pedram A, Razandi M, Evinger AJ, et al. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell. 2009;20(14):3374-3389.
92. Plo I, Laulier C, Gauthier L, et al. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res. 2008;68(22):9404-9412.
93. Xu N, Hegarat N, Black EJ, et al. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol. 2010;190(3):297-305.
94. Mauro M, Rego MA, Boisvert RA, et al. p21 promotes error-free replication-coupled DNA double-strand break repair. Nucleic Acids Res. 2012;40(17):8348-8360.
95. Rössig L, Jadidi AS, Urbich C, et al. Akt-dependent phosphorylation of p21 (Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol. 2001;21(16):5644-5657.
96. Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3(3):245-252.
97. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8(10):1145-1152.
98. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7(2):193-204.
99. Jia Y, Song W, Zhang F, et al. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene. 2012;32(15):1943-1949.
100. Schultze SM, Jensen J, Hemmings BA, et al. Promiscuous affairs of PKB/AKT isoforms in metabolism. Arch Physiol Biochem. 2011;117(2):70-77.